ConcertAI, which develops AI solutions and has a repository of cancer data, said it is embarking on a five-year collaborative research program with the U.S. Food and Drug Administration (FDA) to evaluate the real-world outcomes and safety of cancer treatments.
The collaboration will utilize ConcertAI’s oncology real-world data (RWD) and advanced AI technology solutions to derive real-world evidence (RWE) across a variety of clinical and regulatory use cases. The agreement is with the FDA’s Center for Drug Evaluation and Research (CDER), Office of Clinical Pharmacology, and Office of Translational Science.
Specifically, researchers will look to use technologies that can aid in developing RWE to define strategies to improve patient clinical treatment outcomes; optimize the design of clinical trials; and inform approaches to RWD-enabled safety assessments.
